Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Rosenblatt Securities lifted its price target on Fortinet to $100 from $85 and moved the stock from Neutral to Buy following channel checks that signaled stronger-than-expected demand. The firm highlighted reseller execution, a broad hardware refresh cycle, SASE adoption tied to firewall replacements, and tax incentives as contributors to what it v…
H.C. Wainwright reiterated a Buy rating and maintained a $90 per share 12-month price target on Halozyme Therapeutics (NASDAQ: HALO) after the company raised its FY25 revenue guidance and narrowed royalty revenue expectations. The analyst firm cited stronger visibility into ENHANZE royalty streams and recent business development activity as support…
Scotiabank trimmed its 12-month price objective for Microsoft to $600 from $650 while retaining a Sector Outperform rating after the company’s fiscal second-quarter report. The bank described results as "very solid" but highlighted Azure revenue growth that missed buy-side expectations in consecutive quarters, attributing part of the shortfall to h…
H.C. Wainwright has reaffirmed a Buy rating and a $7.00 price target for OKYO Pharma Ltd. after a Type C meeting with the U.S. Food and Drug Administration validated the company’s proposed primary endpoint and supported key elements of the Phase 2b/3 trial design for urcosimod in neuropathic corneal pain (NCP). The FDA’s feedback included confirmat…
H.C. Wainwright has reiterated its Buy rating and $34.00 price target on Regenxbio (RGNX) following clinical holds imposed by the FDA on two gene therapy programs after a tumor was found in a participant from the RGX-111 trial. The firm noted preliminary genetic evidence of AAV integration linked to proto-oncogene overexpression, while other analys…
H.C. Wainwright increased its price objective for Integra Resources Corp. to $7.25 from $5.00 and kept a Buy rating after the company delivered annual gold output within management guidance and generated meaningful revenues and EBITDA over the last twelve months. Management continues operational execution at Florida Canyon while advancing technical…
Scotiabank increased its price objective for Meta Platforms Inc. to $700 from $685 while retaining a Sector Perform rating, following the company's stronger-than-expected fourth-quarter results. The update comes as Meta reported notable revenue growth, provided aggressive first-quarter guidance, and reiterated expectations that fiscal 2026 operatin…
Jefferies raised its price objective for GE Vernova (GEV) to $930 from $865 and reiterated a Buy rating after the company’s fourth-quarter earnings call. The broker highlighted a potential 10-20 point incremental margin upside that could push Power equipment EBITDA to around 30%. Several analysts have increased earnings estimates and price targets …
Status, an established open-source project in the Ethereum ecosystem, has unveiled a refreshed unified application, launched a satirical sci-fi animated series called USS Status, and announced Status Network - a gasless Layer 2 built on the Linea zkEVM stack. The release bundles a privacy-first mobile and desktop app with features such as encrypted…
Stifel expects the UK technology sector to enter 2026 from a stronger position as macro pressures ease, customer budgets recover and corporate priorities shift toward profitable growth rather than pure revenue expansion. The broker highlights three companies - Kainos Group, Seeing Machines and Concurrent Technologies - that combine exposure to stru…
Summit Therapeutics Inc. (NASDAQ:SMMT) saw its stock rise 7% Thursday morning after the U.S. Food and Drug Administration accepted the company's Biologics License Application for ivonescimab used with chemotherapy to treat certain EGFR-mutated non-squamous non-small cell lung cancer patients. The FDA has established a Prescription Drug User Fee Act…
Wedbush updated its price objective on IBM to $340 from $325 and kept an Outperform rating, pointing to acceleration in the company’s generative AI business. IBM reported revenue and segment results that beat consensus, a rising GenAI backlog, improved free cash flow and margin metrics that supported several subsequent analyst target increases acro…
H.C. Wainwright raised its price target on Nurix (NRIX) to $32.00 from $31.00 while keeping a Buy rating after the company's fourth-quarter fiscal 2025 results. The updated target implies about 79% upside from the current share price of $17.87 and sits above the analyst consensus average of $27.70. Nurix reported a net loss of $0.82 per share for t…
H.C. Wainwright upgraded Korro Bio Inc. (KRRO) from Neutral to Buy and set a $20.00 price target after the company presented KRRO-121, a liver-targeted RNA editing candidate aimed at stabilizing glutamine synthetase to preserve ammonia clearance. The firm added the asset to its model at a 20% probability of approval and projected $2 billion in peak…
India will rebase its consumer price index to 2024 and reduce the share of food in the CPI basket to 36.75% under a revamped series. The statistics ministry said the update expands major spending groups from six to 12, introduces an overlapping year in 2025 for statistical conversion, and brings new items such as e-commerce prices into inflation tr…
RBC Capital Markets cut its rating on OMV AG to 'underperform' from 'sector perform' and trimmed its price target to €46 from €50, pointing to near-term headwinds across chemicals, European gas exposure and refining. The bank also reduced its 2026 net income forecast and now values OMV at a modest premium to peers on an EV/DACF basis while showing …
Lockheed Martin projected 2026 revenue and earnings above consensus, driven by sustained demand for its fighter jets, missiles and helicopters amid heightened global conflicts. The company reported stronger fourth-quarter sales and a record annual F-35 delivery run, while policy moves have introduced uncertainty around capital-return plans for defe…
International Paper announced plans to split into two publicly traded firms by spinning off its European packaging business. The move follows a major acquisition in Europe and ongoing divestitures tied to that deal. Shares rose about 5% in premarket trading after the announcement. The company cited slowing demand for box shipments in key regions an…
CareCloud is a cloud-native EHR and practice management provider that has pivoted into AI-driven workflows. At roughly $122M market cap and a free cash flow yield approaching 18%, the stock looks cheap relative to its cash generation and EV/EBITDA of 4.8. This trade idea targets a measured long with a clear entry, stop and target and a 180-trading-…
Copper mining equities jumped Thursday after the industrial metal surged to fresh record levels above $14,000 a metric ton. The London Metal Exchange three-month contract rose sharply during Asian trading before trimming gains, while the Shanghai most-active contract closed notably higher. Analysts point to speculative buying, expectations of robus…
U.S. futures inched higher as markets absorbed Federal Reserve policy inaction and a stream of corporate fourth-quarter results. Large-cap technology names showed sharply divergent moves tied to AI investments and cloud performance, while industrials and leisure companies reacted to earnings and guidance.
Berenberg raised its price objective on Lam Research to $265 from $250 while keeping a Buy rating after the company's January earnings call signaled stronger wafer fabrication equipment (WFE) spending ahead. Lam Forecasts WFE capex of $135 billion in 2026 - a 23% increase from $110 billion in 2025 - and expects sequential quarterly revenue growth b…
Raymond James increased its price objective on C.H. Robinson to $215 from $185 and kept an Outperform rating, citing operational changes including lean practices and artificial intelligence deployed since CEO Bozeman's June 2023 arrival. The firm highlighted margin improvement potential despite historically declining operating margins, while other …
Goldman Sachs reaffirmed its Buy rating on Five Below with a $231 price target, pointing to movie licensing opportunities in 2026 as a material but underappreciated contributor to sales growth. Multiple brokerages have lifted price targets following strong holiday results and higher comparable-sales prints, underscoring analyst optimism about the r…
Fractyl Health's stock dropped roughly 35% after the company released six-month randomized midpoint results from its REMAIN-1 study assessing Revita for weight maintenance following GLP-1 discontinuation. Revita-treated patients showed less weight regain than the sham arm at six months and improvements in certain cardiometabolic lipid markers, but …
